Abstract 1447
Background
Pim-1 is an oncogene and has been proved to play pivotal role in proliferation, apoptosis and angiogenesis. Thyroid cancer represents the most common malignancy in the endocrine system and displays a marked increase in the incidence in recent years. Papillary thyroid cancer (PTC) is among the most frequent thyroid malignancies and accounts for more than 85%. Therefore, it is worthwhile to discuss the function of Pim-1 in the development and progression of PTC.
Methods
Gene set enrichment analysis (GSEA) of Pim-1 in the PTC was performed on the TCGA databases. 177 PTC paraffin blocks were selected to make the tissue microarrays and the levels of Pim-1 protein was investigated by immunohistochemistry. Meanwhile, one of the Pim-1 kinase inhibitor, SGI-1776, was used to evaluate the function of Pim-1 on the PTC cell BCPAP and TPC-1. CCK-8 and colony formation assay was carried out to measure the cell proliferation. Apoptosis rate and migration capacity were determined by flow cytometry and wound-healing methods respectively.
Results
GSEA results revealed that Pim-1 expression was significantly associated with the immune system of PTC. IHC result showed that Pim-1 was overexpressed in the PTC tissues compared with normal adjacent tissues. Meanwhile, Pim-1 had a significant relationship with the T-stage, lymph node involvement, capsule invasion and gender. Female patients and patients with higher T-stage, positive lymph node involvement, positive capsule invasion have a higher Pim-1 level. After SGI-1776 treatment, Pim-1 expressions were obviously downregulated in both BCPAP and TPC-1. Decreased Pim-1 led to the proliferation depression, apoptosis rate elevation and the migration capacity reduction in both cell lines.
Conclusions
Taken together, our current data showed the important role of Pim-1 in the tumorigenesis of PTC. High Pim-1 level linked to immune status and aggressive malignant behavior of PTC. It was also suggested that PIM-1 kinase might be a novel molecular biomarker of PTC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Zhejiang Province Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract